BGR Energy receives contract termination from TN Power Corp for major Chennai project worth Rs 2,600 crore
The official termination order was dated July 18, 2025, and was received by the company on July 22, 2025.
In the exchange filings, BGR Energy Systems shared, 'We hereby inform you that the company has received 'termination of contract' letter from Tamil Nadu Power Generation Corporation Ltd (TNGCPL) (erstwhile TANGEDCO). This is with respect to establishment of 1 x 800 MW North Chennai Super Critical Thermal Power Project, Stage III – Balance of Plant (BOP) package along with allied civil works EPC contract of value Rs 2600.02 Crores'
According to the disclosure, TNPGCL cited key project obligations not being fulfilled, incomplete critical systems, and lapses in insurance renewals and guarantee extensions as the reasons behind the decision.
BGR Energy, however, noted that the matter is currently under arbitration before the Hon'ble High Court of Madras and expressed hope for a favorable resolution. The company also clarified that the termination does not have any significant impact on its financials or operations at this stage.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
Kotak Mahindra Bank Q1 results: Net profit down 47% YoY to Rs 3,282 crore, GNPA at 1.48% vs 1.39% QoQ
Kotak Mahindra Bank reported a 47.5% year-on-year (YoY) decline in net profit for the quarter ended June 30, 2025, with Q1 FY26 profit standing at Rs 3,281.68 crore compared to Rs 6,249.82 crore in Q1 FY25. The sharp fall is primarily due to the absence of exceptional gains booked in the same quarter last year. Net Interest Income (NII) grew 6% YoY to Rs 7,259 crore from Rs 6,843 crore, reflecting steady growth in lending and core banking operations. Total income rose to Rs 16,916 crore from Rs 15,675 crore YoY. Operating profit (before provisions) rose to Rs 5,563.69 crore from Rs 5,254.11 crore in the previous year. Provisions and contingencies, however, jumped to Rs 1,207.76 crore from Rs 578.48 crore YoY, impacting the bank's profitability. Asset quality weakened slightly: Gross NPA: Rs 6,637.70 crore (1.48%) vs Rs 5,477.15 crore (1.39%) QoQ Net NPA: Rs 1,530.93 crore (0.34%) vs Rs 1,376.33 crore (0.35%) QoQ Despite steady growth in core income, the YoY profit decline was driven by the high base effect of last year's Rs 3,519.90 crore exceptional gain. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
3 hours ago
- Business Upturn
Alembic Pharma gets USFDA nod for Carbamazepine Extended-Release Tablets
Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Carbamazepine Extended-Release Tablets USP in strengths of 100 mg, 200 mg, and 400 mg. These tablets are the generic version of Tegretol-XR, a widely used anticonvulsant drug developed by Novartis Pharmaceuticals. Alembic's version is therapeutically equivalent to the original, meaning it meets the same standards for quality, strength, and effectiveness. Carbamazepine Extended-Release Tablets are primarily used to treat seizure disorders and are also prescribed for trigeminal neuralgia, a chronic pain condition affecting the facial nerves. According to IQVIA data, the US market for this drug was valued at approximately $71 million for the 12-month period ending March 2025. With this approval, Alembic now has a total of 225 ANDA approvals from the USFDA, which includes 202 final approvals and 23 tentative approvals. About Alembic Pharmaceuticals Founded in 1907 and headquartered in India, Alembic Pharmaceuticals is a vertically integrated pharmaceutical company known for its strong focus on research and development. It manufactures and markets generic drugs across global markets, with several of its facilities approved by top regulatory bodies including the USFDA. In India, Alembic is a leader in branded generics, with a product portfolio promoted by a field force of over 5,500 professionals. Its products are widely recognized and trusted by healthcare professionals and patients alike. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
4 hours ago
- Business Upturn
Nifty top gainers this week (July 26): Eternal, ICICI Bank, Cipla, HDFC Life, Hindalco Industries and more
By Aman Shukla Published on July 26, 2025, 09:45 IST The Indian stock market wrapped up the week ending July 26, 2025, deep in negative territory, extending its losing streak to a fourth consecutive week — the longest such stretch this year and the first since October 2024. Both benchmark indices — BSE Sensex and Nifty 50 — declined by around 0.5% over the week, weighed down by broader market weakness. The Nifty Midcap 100 dropped 1.5%, significantly underperforming the large-cap peers. However, there was a slight silver lining: Nifty Bank bucked the trend and managed a marginal 0.5% gain. Despite the bearish close to the week, several heavyweight stocks in the Nifty 50 index delivered notable weekly gains. Let's take a closer look at the top 10 losers of the Nifty 50 this week, according to Trendlyne. Eternal — up 20.7% this week, closing at ₹310.6 ICICI Bank — up 3.6% this week, closing at ₹1,477.1 Cipla — up 3.4% this week, closing at ₹1,532.5 HDFC Life Insurance — up 3.1% this week, closing at ₹762.4 Hindalco Industries — up 2.6% this week, closing at ₹693.5 SBI Life Insurance — up 2.4% this week, closing at ₹1,832.1 HDFC Bank — up 2.4% this week, closing at ₹2,004.6 Apollo Hospitals — up 2.3% this week, closing at ₹7,468.5 Bharti Airtel — up 1.9% this week, closing at ₹1,937.9 Titan Company — up 1.8% this week, closing at ₹3,462.8 Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash CiplaEternalHDFC LifeHindalco IndustriesICICI BankStock Market Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
